Actualités

West Pharmaceutical Services has been on fire lately. In the past six months alone, the company’s stock price has rocketed 43%, reaching $339.52 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.

RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.

Stryker tops Q2 estimates as sales regain momentum after a cyber disruption, but narrowed 2026 guidance weighs on shares, sending them down 7.8% in after-hours trading.

Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.

GE HealthCare beats second-quarter estimates as revenues rise 5.7%, orders climb 11.1% and backlog hits a record $23.9 billion.

DVA's IKC momentum, higher 2026 guidance and technology investments support growth, while reimbursement and payer-mix risks cloud the outlook.

TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.

STE is expected to deliver fiscal first-quarter revenue and EPS growth, driven by strength in Healthcare, continued momentum in AST, and healthy demand in Life Sciences.

MiniMed expands Flex access to Medicare beneficiaries, widening availability of its app-controlled pump and automated insulin delivery technology.

IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.

MNST, CRS and USIO highlight Zacks strategies that outperformed amid a volatile market.

West Pharmaceutical Services (NYSE:WST) has entered new long-term exclusive and non-exclusive distributorship agreements with Daikyo Seiko. West Pharmaceutical will distribute Daikyo products outside Japan, while Daikyo will distribute more West products within Japan. The agreements are structured to run over the next decade, reinforcing the companies' cross-border partnership in drug packaging technologies. West Pharmaceutical Services comes into this new distribution arrangement with...

A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million

COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.

RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.

SOLV's innovation, cost savings and strong segment demand support growth, while raw material cost increases remain a key risk.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

West Pharmaceutical Services (NYSE:WST) raised its full-year 2026 outlook after reporting second-quarter results that topped management’s expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers. Chief Executive Officer and Board C

Moby summary of West Pharmaceutical Services, Inc.'s Q2 2026 earnings call

West Pharmaceutical Services Inc (WST) reports robust Q2 results with significant revenue and EPS growth, while raising full-year guidance amidst global expansion and strategic initiatives.

WST tops Q2 earnings and revenue estimates, lifts its 2026 EPS outlook and sees shares surge as high-value products fuel strong growth.

QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.

SNN expands ASC Solutions with an integrated platform, analytics and partners to boost efficiency, growth and patient outcomes in outpatient care.

OPKO Health's growth outlook rests on RAYALDEE, BioReference gains and partnerships, though losses and pipeline risks persist.

CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.

While the top- and bottom-line numbers for West Pharmaceutical (WST) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.